STERIS (STE) Q2 2026: Service Revenue Jumps 13% as Margin Expansion Outpaces Tariff Headwinds
Service-driven margin expansion defined STERIS’s Q2, with both Healthcare and AST segments leveraging volume and pricing to offset inflation and tariffs. Executives raised full-year guidance across revenue, margins, and cash flow, citing broad-based strength and a robust capital equipment backlog. Investors should monitor normalization in service pricing and persistent input cost pressures as key variables for the second half.
Summary
- Service Outperformance Drives Margin Gains: Both Healthcare and AST segments delivered double-digit service growth, powering EBIT margin expansion despite cost headwinds.
- Capital Equipment Backlog Provides Visibility: Large backlogs in Healthcare and Life Sciences support near-term revenue stability, but shipment timing remains a wild card.
- Guidance Raised on Broad-Based Execution: Management increased full-year outlook for revenue, earnings, and free cash flow, underscoring confidence in operational momentum.
Performance Analysis
STERIS delivered 10% reported revenue growth and 9% constant currency organic growth in Q2, with volume and pricing both contributing. The company’s gross margin expanded 60 basis points to 44.3%, as productivity and price actions more than offset inflation and tariff costs. EBIT margin improved 90 basis points to 23.1%, driven by operating leverage and cost containment, even as tariffs and labor/material inflation persisted.
Segment performance was led by Healthcare and AST, where service revenues grew 13% in both units, outpacing equipment and consumables. Life Sciences rebounded with a 12% revenue increase, propelled by a 39% surge in capital equipment shipments and a 50%+ increase in backlog. Free cash flow for the first half hit $527.7 million, reflecting earnings growth and working capital gains, while leverage remained conservative at 1.2x EBITDA.
- Healthcare Margin Resilience: EBIT margin in Healthcare rose to 25.1%, as volume, pricing, and restructuring offset a $12 million tariff impact.
- AST Mix Shift: Higher service mix and less equipment exposure drove AST’s EBIT margin up 250 basis points to 45.3%.
- Life Sciences Capital Recovery: Capital equipment shipments rebounded, but margins declined 70 basis points due to inflation and tariffs.
Management’s raised guidance reflects confidence in continued broad-based execution, though normalization in service pricing and persistent input cost pressures remain key watchpoints for the second half.
Executive Commentary
"Service continued its streak of outperformance growing 13% in the second quarter. Consumables also performed well with growth of 10%. Healthcare capital equipment revenue increased 4% in the quarter with backlog of over 400 million."
Dan Crestio, President and CEO
"Gross margin for the quarter increased 60 basis points compared with the prior year to 44.3%. Positive price and productivity, primarily driven by volume, more than offset increased inflation and tariff costs."
Karen Burton, Senior Vice President and CFO
Strategic Positioning
1. Services as the Margin Engine
Sustained double-digit service growth in both Healthcare and AST segments has become STERIS’s most reliable profit driver. Service, defined as maintenance, repair, and instrument processing, benefits from pricing power and stable MedTech volumes. Management signaled a potential normalization in growth rates as labor inflation cools, but expects margins to remain stable due to offsetting cost trends.
2. Capital Equipment Backlog and Visibility
Healthcare and Life Sciences capital equipment backlogs exceed $400 million and $114 million, respectively, providing near-term revenue visibility. However, shipment timing remains variable, and management acknowledged “tough comps” in coming quarters, especially for Healthcare capital. Order rates remain strong, but the capital cycle is inherently lumpy.
3. Pricing and Productivity as Inflation Offsets
STERIS’s ability to pass through price increases and drive productivity gains was critical in offsetting 90 basis points of tariff headwinds and 130 basis points of labor/material inflation. The company’s restructuring initiatives and global footprint support continued cost discipline, but management remains vigilant on input cost volatility.
4. Capacity Expansion in AST
AST (Applied Sterilization Technologies) continues to invest in capacity, with several expansions completed and more underway. Management highlighted the multi-year timeline for new plants, but indicated that most geographies now have adequate headroom to support growth, reducing risk of near-term constraints.
5. Life Sciences Recovery and Bioprocessing Trends
Life Sciences capital equipment growth of 39% signals a rebound from prior-year lows, aided by some benefit from pharma manufacturing reshoring. While management noted more “noise than substance” in reshoring trends, any uptick in pharma capacity expansion generally supports STERIS’s GMP (Good Manufacturing Practice) equipment business.
Key Considerations
STERIS’s Q2 results highlight broad-based execution, with services, pricing, and operational discipline offsetting persistent cost headwinds. The company’s raised outlook is underpinned by robust backlogs and a diversified revenue base, but investors should weigh several factors as the year progresses.
Key Considerations:
- Service Growth Normalization: Management expects service growth to moderate as labor inflation stabilizes, with margin impact cushioned by easing wage pressure.
- Capital Equipment Shipment Timing: Large backlogs in Healthcare and Life Sciences provide visibility, but shipment timing could cause quarterly volatility, especially against tough prior-year comps.
- Tariff and Inflation Pressures: Tariffs and input inflation remain meaningful headwinds, with 220 basis points of margin drag in Q2; ongoing price and productivity actions are critical.
- Cash Flow Seasonality: First-half free cash flow was unusually strong due to early earnings and working capital gains; management signaled some conservatism in full-year guidance.
Risks
STERIS faces persistent inflationary and tariff headwinds that could pressure margins if price realization or productivity gains falter. Capital equipment shipment timing remains a risk given large backlogs and lumpy order patterns. Normalization in service pricing and demand for consumables could temper top-line momentum in the second half, while regulatory or reimbursement changes in healthcare remain ongoing uncertainties.
Forward Outlook
For Q3 and Q4, STERIS guided to:
- 8% to 9% as reported revenue growth for the full year
- 7% to 8% constant currency organic revenue growth
- EBIT margin improvement of 10 to 20 basis points
- Free cash flow of $850 million (raised by $30 million)
Management expects:
- All three segments to grow 7% to 8% organically for the year
- AST services up 9% to 10%, with capital equipment declining versus tough comps
- Effective tax rate to increase by 50 basis points to 24%
Takeaways
STERIS’s Q2 demonstrated the power of its service model and disciplined cost management, enabling outperformance and a guidance raise despite macro headwinds.
- Service Strength: Double-digit service growth and pricing power remain the company’s margin engine, but normalization is expected as labor inflation cools.
- Capital Backlog Visibility: Record backlogs in Healthcare and Life Sciences support near-term growth, though shipment timing will drive quarterly variability.
- Cost Discipline Critical: Ability to offset inflation and tariffs through pricing and productivity will remain a key determinant of margin trajectory in the second half.
Conclusion
STERIS enters the back half of fiscal 2026 with strong momentum, underpinned by service outperformance and a robust backlog. Investors should focus on the sustainability of pricing, input cost trends, and the timing of capital equipment shipments as key drivers of second-half results.
Industry Read-Through
STERIS’s strong service growth and margin expansion highlight the value of recurring revenue and pricing agility for MedTech and life sciences peers facing inflation and tariff headwinds. Robust capital equipment backlogs suggest continued demand for hospital and pharma infrastructure, but shipment timing and supply chain constraints will remain sector-wide issues. Bioprocessing recovery and pharma reshoring are emerging themes to watch, with potential positive spillover for suppliers with global footprints and capacity expansion plans. Investors should monitor normalization in service pricing and labor costs as a bellwether for margin trends across the healthcare supply chain.